Figure 5. Pharmacologic modeling defines... | American Society of Hematology

Figure 5.

Pharmacologic modeling defines FXIII-A2 and -B behavior in mice and humans. (A-B) Observed concentrations of FXIII-A2 (A) and FXIII-B (B) antigen after the administration of 4 mg/kg (open symbols) or 8 mg/kg (closed symbols) rFXIII-A2 to F13a1–/– mice; model-predicted concentrations are overlaid (red lines). (C-D) Observed concentrations of FXIII-A2 (C) and FXIII-B (D) (lower detection limit 0.845 μg/mL) per nominal time after the administration of 35 IU/kg rFXIII-A2 to humans with FXIII-A deficiency; model-predicted concentrations are overlaid (red lines).

Pharmacologic modeling defines FXIII-A₂ and -B behavior in mice and humans. (A-B) Observed concentrations of FXIII-A₂ (A) and FXIII-B (B) antigen after the administration of 4 mg/kg (open symbols) or 8 mg/kg (closed symbols) rFXIII-A₂ to F13a1^–/– mice; model-predicted concentrations are overlaid (red lines). (C-D) Observed concentrations of FXIII-A₂ (C) and FXIII-B (D) (lower detection limit 0.845 μg/mL) per nominal time after the administration of 35 IU/kg rFXIII-A₂ to humans with FXIII-A deficiency; model-predicted concentrations are overlaid (red lines).

This Feature Is Available To Subscribers Only